Ask AI
ProCE Banner Activity

Why I Have Renewed Hope for Better Treatment of Platinum-Resistant Ovarian Cancer

Clinical Thought
In this commentary, Kathleen Moore, MD, discusses new approaches and new agents that may meaningfully improve outcomes for women with platinum-resistant ovarian cancer.

Released: August 11, 2022

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AstraZeneca

GlaxoSmithKline

Merck Sharp & Dohme Corp.

Regeneron Pharmaceuticals, Inc. and Sanofi Genzyme

Faculty Disclosure

Primary Author

Kathleen N. Moore, MD, MS, FASCO

Deputy Director
Co-Director Cancer Therapeutics Program
Stephenson Cancer Center at OU Health
Professor, Gynecologic Oncology
University of Oklahoma, HSC
Oklahoma City, Oklahoma

Kathleen Moore, MD: consultant/advisor/speaker: AstraZeneca, Aravive, Alkermes, BluePrint Pharma, Eisai, EMD Serono, Elevar, Genentech/Roche, Jiangsu Hengrui, Immunogen, INXmed, I-Mab, Mereo, Mersana, Myriad, Novartis, Onconova, Oncxerna, Tarveda, Verastem, VBL Therapeutics; researcher: PTC Therapeutics, Lilly, Merck, GlaxoSmithKline/Tesaro.